DRREDDY Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹8,100 Cr
verified against source
Revenue YoY
-5.6%
reported change
EBITDA
₹1,109 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Dr. Reddy's Q1 FY27 reported a 5.6% revenue decline to ₹8,871 crore, impacted by lower lenalidomide revenues and a ₹240 crore semaglutide API provision. Excluding the semaglutide impact (~₹290 crore including lost production incentives and inventory provisions), EBITDA margin would have been 15.4% versus reported 12.5%. The base business delivered double-digit growth across all geographies—India grew 17% YoY, Emerging Markets surged 31%, and North America base business excluding lenalidomide showed double-digit growth. Management confirmed targeting ~20% EBITDA margins going forward assuming November semaglutide resumption, with ₹1,800 crore capex guidance for FY27. Key catalysts include the December 2026 abatacept PDUFA and resolution of USFDA's 7 observations at Bachupalli biologics facility. Risks include semaglutide API re-validation failure (80-90% confidence per CEO), potential US tariff implications on 25-30% CMO-manufactured revenues, and continued price erosion in US generics.
Colored figures show movement against the previous available record.
Guidance to track
- Management maintained 20% EBITDA margin guidance excluding semaglutide impact, expecting to stay in that neighborhood including Q2 even without semaglutide resumption, with margins improving upon November supply resumption.
- Targeting completion of API testing by third week of September 2026, with supply to partners to resume by November 2026, enabling 6-7 million pens to be supplied between November and March.
- Full-year capex guidance of around ₹1,800 crore, reduced from the earlier 2,500-2,700 crore range, reflecting lower infrastructure buildout as biologics and peptide facilities approach completion.
- R&D expenditure expected to be in the 7-8% range, with majority of spending directed toward products launching between 2034-2040, including additional biosimilars and peptides.
Risks flagged
- Root cause analysis complete with 80-90% confidence of resolution by September 23, but API re-validation could fail, delaying November supply resumption and impacting 6-7 million pen opportunity and potential PLA incentives.
- USFDA issued 7 observations at Bachupalli biologics facility (PLI completed June 2026); while all observations deemed addressable and responses submitted, additional GMP queries or clinical data requests could delay December 2026 PDUFA goal date.
- CEO explicitly admitted R&D productivity failures in certain complex generics (iron sucrose, conjugated estrogen, peptides) over past 4-5 years, though believes corrections were made—products in development now reflect 10-12 year lead times.
- US President announced potential tariffs on generics; while management downplayed immediate impact citing 2-year runway and 25-30% US manufacturing already via CMO, concrete mitigation strategy remains undefined beyond monitoring IPA/industry association engagement.
Key quotes
- The root cause is identified. The success rate is high... somewhere between 80 to 90%. But there is a chance that it will fail. I just want to make sure it's not 100%.
- The answer is yes, we did have these issues [R&D productivity]. I believe that we corrected it. Obviously as we know very well the R&D expenses of today's product that we will launch on average 10 to 12 years from now.
- The opportunity is about three to four million pens assuming that we are coming back in November.
Research modules